Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 415

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 415
---
us forms a part.

Oramed Letter Agreements

On
September 20, 2024, the Company and Oramed entered into a Letter Agreement (the “Oramed Letter Agreement”), pursuant to which the Company agreed to pay to Oramed $2,000,000 (the “Specified September Payment”) on
September 23, 2024, which payment was applied as follows: (i) $1,700,000 of such payment to the amortization payment due under the Oramed Note on the March 21, 2025 and (y) $300,000 of such payment to purchase warrants (the
“Purchased Warrants”) to purchase an aggregate of 114,285 (on a post-Reverse Stock Split basis) shares of Common Stock with an exercise price of $402.50 per share (on a post-Reverse Stock Split basis).

Pursuant to the Oramed Letter Agreement, the parties agreed that, notwithstanding the definition of the “Exercise Eligibility
Date” in the CS-5 Warrant, Oramed may immediately exercise the CS-5 Warrant with respect to up to 1,062,500 (subject to adjustment as provided therein) shares of
Common Stock subject to such warrant at any time after September 20, 2024. The parties further agreed, upon receipt of the Specified September Payment, (i) that notwithstanding the minimum Liquidity (as defined therein) requirements set
forth in Section 7(b)(x) of the Oramed Note, the Company and its Subsidiaries (as defined therein) shall be required to maintain the following minimum liquidity during the specified time periods instead: from and after September 19, 2024
until the Maturity Date, $0, and (ii) to extend the due date of the $20,000,000 amortization payment from September 23, 2024 to September 30, 2024.

On October 2, 2024, the Company and Oramed entered into a Consent and Side Letter (the “Consent and Side Letter”), pursuant
to which Oramed agreed to extend the due date of the September 23, 2024 payment to October 7, 2024. Oramed has agreed to further extend such due date to October 8, 2024 to allow additional time to close the Company’s convertible
debt financing that was announced earlier the same day.

The above descriptions of